<DOC>
	<DOCNO>NCT02262923</DOCNO>
	<brief_summary>Metoclopramide dopamine D2 receptor antagonist antiemetic gastrokinetic property approve use pregnant woman . Women polycystic ovary syndrome ( PCOS ) find low dopaminergic tone increase ovarian vascularity vascular endothelial growth factor ( VEGF ) level compare control . During ovarian stimulation , PCOS patient exhibit great sensitivity gonadotropin increase follicular development . Administration dopamine D2 antagonist may mimic low dopaminergic tone note PCOS patient , increase VEGF level , angiogenesis , subsequently improve follicular growth ovarian stimulation . This strategy could use improve IVF outcome poor responder . The investigator hypothesize , compare gonadotropin use alone , use metoclopramide combination gonadotropin poor responder undergo IVF result increase number mature oocyte obtain oocyte retrieval improve IVF outcome .</brief_summary>
	<brief_title>Dopamine D-2 Antagonist Use Poor Responders IVF : Randomized Controlled Trial</brief_title>
	<detailed_description>Poor responder constitute significant challenging population woman treat vitro fertilization ( IVF ) . This population include woman respond sub-optimally conventional ovarian stimulation poor follicular recruitment . The estimated incidence poor ovarian response range 9-26 % . Patients PCOS opposite end spectrum poor responder . They often exquisitely sensitive ovarian stimulation predispose over-respond development ovarian hyperstimulation syndrome ( OHSS ) . Understanding underlying mechanism enhance sensitivity may provide insight treatment poor responder . VEGF glycoprotein produce ovarian granulosa cell enhance vascular permeability angiogenesis , implicate pathogenesis OHSS . After ovulation trigger LH hCG , follicular expression VEGF increase , crucial corpus luteum function steroidogenesis . However , excessive VEGF production lead third-space shifts fluid , ascites , life-threatening feature OHSS . Serum concentration granulosa cell expression VEGF show high woman PCOS control . Interestingly , compare control , patient PCOS also show low level neurotransmitter dopamine dopamine D2 receptor level ovary . Administration dopamine D2 agonists show animal human study decrease ovarian VEGF production reduce risk OHSS . In study , investigator propose novel approach administer dopamine D2 antagonist poor responder mimic low dopaminergic tone PCOS patient , goal increase VEGF production follicular development ovarian stimulation . Metoclopramide dopamine D2 antagonist antiemetic prokinetic property establish safety profile pregnancy . The investigator hypothesis metoclopramide use prior , conjunction , conventional gonadotropin stimulation improve IVF outcome poor responder .</detailed_description>
	<mesh_term>Metoclopramide</mesh_term>
	<mesh_term>Dopamine D2 Receptor Antagonists</mesh_term>
	<mesh_term>Dopamine</mesh_term>
	<criteria>Poor responder undergo repeat IVF cycle define woman undergone least one previous IVF cycle few 4 oocyte retrieve least one following : Advanced age ( â‰¥40 year ) risk factor poor ovarian response Abnormal ovarian reserve test ( antral follicle count ( AFC ) &lt; 57 antimullerian hormone ( AMH ) level &lt; 3.67.9 pmol/L ) Subjects previously recruit study either cycle cancellation , underwent retrieval drop study . Women contraindication allergy metoclopramide . Women elevate prolactin level know pituitary microadenomas macroadenoma . Women take dopamine agonist medication .</criteria>
	<gender>Female</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>43 Years</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>